(Q43461402)

23 November 2017

title

Is there a role for postremission therapy in older adults with acute myelogenous leukemia (AML)? (English)

1 reference

23 November 2017

Rowe JM

1

1 reference

23 November 2017

publication date

1 August 2005

1 reference

23 November 2017

1 reference

23 November 2017

volume

19

1 reference

23 November 2017

issue

8

1 reference

23 November 2017

page(s)

1324-1327

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403827

23 November 2017

exact match

0 references

cites work

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Treatment of acute myelogenous leukemia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

7 January 2021

Clinical trials in AML of the elderly: should we change our methodology?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

7 January 2021

Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

7 January 2021

6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

7 January 2021

Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403827

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403827

1 reference

Dimensions Publication ID

23 November 2017

1039144134

0 references

1 reference